Position in ZNTL
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$1,427,570
+$603,972 QoQ
Shares Held
610,073
0.0% QoQ
Ownership
0.857%
of shares outstanding
% of Portfolio
0.32%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ZNTL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Almitas Capital LLC holds $45,111,127 across 8 Biotechnology names. ZNTL ranks #7 (3.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | DSGN |
Design Therapeutics, Inc.
|
1,530,335 | $16,282,764 | |
| 2 | LYEL |
Lyell Immunopharma, Inc.
|
577,807 | $11,590,808 | |
| 3 | ALXO |
Alx Oncology Holdings Inc
|
3,173,834 | $6,363,537 | |
| 4 | ANTX |
AN2 Therapeutics, Inc.
|
1,479,129 | $5,058,621 | |
| 5 | ANRO |
Alto Neuroscience, Inc.
|
78,520 | $1,765,129 | |
| 6 | RLYB |
Rallybio Corp
|
191,206 | $1,715,117 | |
| 7 | ZNTL |
Zentalis Pharmaceuticals, Inc.
This page
|
610,073 | $1,427,570 | |
| 8 | CABA |
Cabaletta Bio, Inc.
|
337,391 | $907,581 |
All Filings in ZNTL
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,427,570 | 610,073 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $823,598 | 610,073 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $690,556 | 457,322 | Shares | Sole | 2025-11-17 | |
| 2025-06-30 | $1,855,148 | 1,599,266 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $2,720,364 | 1,710,921 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $4,929,494 | 1,626,896 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $3,536,215 | 960,928 | Shares | Sole | 2024-11-14 | |
| No filing history on record for this holder in this stock. | ||||||